Samsung BioLogics said on March 17 that it has signed a consignment development (CDO) partnership with Taiwan's APRINOIA, which is developing a cure for Alzheimer's disease.
APRINOIA is a bio-venture company in Taiwan that is developing medical equipment and treatments to diagnose degenerative neurological diseases such as Alzheimer's Disease.
Through the deal, Samsung BioLogics plans to provide development services ranging from developing cell stocks of Alzheimer's drug candidate materials to process development, clinical sample production and submission of clinical trial plans to APRINOIA. It will also be responsible for global production of nonclinical and clinical materials.
Samsung BioLogics plans to speed up its advance into the Chinese market based on its partnership with APRINOIA. It is currently discussing additional contracts with more than 20 Chinese customers.
"With the development and production capabilities of Samsung Biologics, the company will successfully lead the development of its customers' products," said Kim Tae-han, president of Samsung BioLogics.
Samsung BioLogics has carried out a total of 48 CDO projects so far to support bio-venture companies' drug development, including application for approval for clinical trials and support for technology transfer (license out).
